XXXX --does adjuvant irradiation contribute to cure?

@entity1 @entity6012 @entity66 @entity5 @entity521 @entity34
Twenty-one @entity1 with @entity34 diagnosed between 1973 and 1983 were analyzed retrospectively. Median age at diagnosis was eleven months (1 week to 153 months). @entity5 was above the diaphragm in 67% and below the diaphragm in 33%. All @entity1 underwent surgical resection and pathologic diagnosis was @entity521 in 76% and @entity6012 in 24%. Regional lymph nodes were positive in three of eleven @entity1 sampled. Sixty-seven percent had gross @entity66 , and thirty-three percent had microscopic @entity66 . Seventeen @entity1 received postoperative irradiation and none has relapsed (median follow-up 57 months). Four @entity1 received surgery alone (median follow-up 24 months); one local relapse occurred in this group and was subsequently treated with irradiation. All @entity1 are alive and disease free, with a median length of follow-up of 55 months. Radiation dosage was 1000-1800 rad in @entity1 less than 12 months of age, and 1800-3000 rad in those greater than 12 months of age at diagnosis. The high disease-free survival rate in both groups of @entity1 , but especially in the group receiving adjuvant irradiation, emphasizes the need for a controlled, prospective study to determine which @entity34 @entity1 , if any, would be benefitted by postoperative irradiation.
